2004
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells
Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.Peer-Reviewed Original ResearchConceptsBone morphogenetic proteinProstate cancer cellsHuman prostate cancer cellsLoss of expressionProstate cancer patientsBMP-RIICancer patientsGleason scoreBMP receptor type IABone morphogenetic protein receptor type IICancer cellsSignificant associationHuman prostate cancer cell linesBiochemical recurrence-free rateExpression of BMPRsRecurrence-free rateProstate cancer cell linesCell linesTumor growth rateReceptor type IIParental cell lineCancer cell linesMorphogenetic proteinsClinical stagePrognostic valueTissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy
Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63: 1191-1197. PMID: 15183988, DOI: 10.1016/j.urology.2003.12.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDisease ProgressionFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedMultivariate AnalysisNeoplasm StagingProstateProstate-Specific AntigenProstatectomyProstatic HyperplasiaProstatic NeoplasmsReceptors, Transforming Growth Factor betaTransforming Growth Factor betaTransforming Growth Factor beta1ConceptsPlasma TGF-beta1 levelsTGF-beta1 levelsAbnormal expressionTGFbeta-RIITGFbeta-RIBiochemical progressionRadical prostatectomyProstate cancerPathologic Gleason scoreSeminal vesicle involvementSurgical margin statusProstate cancer featuresTissue expressionGrowth factor-β1TGF-beta1 overexpressionConsecutive patientsExtracapsular diseaseMargin statusPathologic featuresGleason scoreBlood levelsLoss of expressionPrognostic markerImmunohistochemical stainingFactor-β1
2001
Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder
Kim J, Shariat S, Kim I, Menesses‐Diaz A, Tokunaga H, Wheeler T, Lerner S. Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001, 92: 1475-1483. PMID: 11745225, DOI: 10.1002/1097-0142(20010915)92:6<1475::aid-cncr1472>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsTransitional cell carcinomaBladder transitional cell carcinomaInvasive tumor stageOverexpression of TGFDisease progressionIndependent predictorsCell carcinomaTumor stageLoss of expressionTGF betaGrowth factorDisease-specific survivalAltered expressionExpression of TGFGrowth factor-β1Lymphovascular invasionRadical cystectomySpecific survivalClinical outcomesCystectomy specimensUrinary bladderImmunohistochemical stainingBlinded fashionFactor-β1Predictive value
1998
Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.
Kim I, Ahn H, Lang S, Oefelein M, Oyasu R, Kozlowski J, Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clinical Cancer Research 1998, 4: 1625-30. PMID: 9676836.Peer-Reviewed Original ResearchConceptsHuman prostate cancer tissuesClinical tumor stageProstate cancer patientsProstate cancer tissuesGleason scoreLoss of expressionTGF-betaRIRecurrence rateTumor stageCancer patientsRadical prostatectomyCancer tissuesSurvival rateSignificant associationPotential prognostic valuePotential prognostic markerReceptor type IGrowth factor betaGrowth factor beta receptorTGF-beta receptorsInitial diagnosisPoor prognosisPrognostic valueDisease progressionPrognostic marker
1996
Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.
Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. PMID: 9816295.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IAnimalsAntibody SpecificityHumansImmunohistochemistryMaleProstatic NeoplasmsProtein Serine-Threonine KinasesRabbitsReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTumor Cells, CulturedConceptsType II receptorHuman prostate cancer tissuesProstate cancer tissuesII receptorsProstate cancer cellsLoss of expressionTumor gradeTGF-beta receptorsCancer tissuesProstate tissueTGF-beta1 type IProstate cancer cell growthMalignant human prostate tissueType ICancer cellsHuman prostate cancer cellsGrowth factor-beta type IProstate cancer casesHuman prostate cancerBenign prostate tissueCancer cell growthHuman prostate tissueTGF-beta type IGrowth factor beta1Benign human prostate